PE20220135A1 - Polimorfos de un inhibidor de cinasas macrociclicas - Google Patents

Polimorfos de un inhibidor de cinasas macrociclicas

Info

Publication number
PE20220135A1
PE20220135A1 PE2021002184A PE2021002184A PE20220135A1 PE 20220135 A1 PE20220135 A1 PE 20220135A1 PE 2021002184 A PE2021002184 A PE 2021002184A PE 2021002184 A PE2021002184 A PE 2021002184A PE 20220135 A1 PE20220135 A1 PE 20220135A1
Authority
PE
Peru
Prior art keywords
polymorphs
kinase inhibitor
macrocyclic kinase
mammals
cancer
Prior art date
Application number
PE2021002184A
Other languages
English (en)
Inventor
Wei Deng
Evan W Rogers
Yuelie Lu
Han Zhang
Jing Liu
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of PE20220135A1 publication Critical patent/PE20220135A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta divulgacion se refiere a polimorfos de (3aR,11S,20aS)-7-fluoro-11-metil-2,3,3a, 12,13,20a-hexahidro-1H, 5H-17,19-(meteno)ciclopenta[5,6][1,4]oxazino[3,4-i]pirazolo[4,3-f]pirido[3,2-l][1,4,8,10]oxatriazaciclotridecina-14(11H)-ona que son utiles en el tratamiento de enfermedades, como el cancer, en mamiferos. Esta divulgacion tambien se refiere a composiciones que incluyen tales polimorfos. Dichos polimorfos son utiles en el tratamiento de enfermedades, tales como cancer, en mamiferos, especialmente en humanos.
PE2021002184A 2019-06-19 2020-06-16 Polimorfos de un inhibidor de cinasas macrociclicas PE20220135A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US202063036102P 2020-06-08 2020-06-08
PCT/US2020/037892 WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Publications (1)

Publication Number Publication Date
PE20220135A1 true PE20220135A1 (es) 2022-01-27

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002184A PE20220135A1 (es) 2019-06-19 2020-06-16 Polimorfos de un inhibidor de cinasas macrociclicas

Country Status (14)

Country Link
US (1) US20220411439A1 (es)
EP (1) EP3986413A4 (es)
JP (1) JP2022537385A (es)
KR (1) KR20220046549A (es)
CN (1) CN114025765A (es)
AU (1) AU2020294627A1 (es)
BR (1) BR112021025786A2 (es)
CA (1) CA3143043A1 (es)
CO (1) CO2022000405A2 (es)
IL (1) IL288982A (es)
MX (1) MX2021015756A (es)
PE (1) PE20220135A1 (es)
TW (1) TW202115090A (es)
WO (1) WO2020257169A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63829B1 (sr) * 2014-01-24 2023-01-31 Turning Point Therapeutics Inc Diaril makrociklična jedinjenja kao modulatori protein kinaza
MX2017017097A (es) * 2015-07-02 2018-05-23 Tp Therapeutics Inc Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
US10294242B2 (en) * 2015-07-06 2019-05-21 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
ES2818528T3 (es) * 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
CN110891954A (zh) * 2017-07-14 2020-03-17 葛兰素史密斯克莱知识产权发展有限公司 富含亮氨酸的重复激酶2的抑制剂
JP7194188B2 (ja) * 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物

Also Published As

Publication number Publication date
AU2020294627A1 (en) 2022-02-17
CO2022000405A2 (es) 2022-04-29
CA3143043A1 (en) 2020-12-24
KR20220046549A (ko) 2022-04-14
WO2020257169A1 (en) 2020-12-24
EP3986413A1 (en) 2022-04-27
TW202115090A (zh) 2021-04-16
BR112021025786A2 (pt) 2022-02-01
IL288982A (en) 2022-02-01
CN114025765A (zh) 2022-02-08
EP3986413A4 (en) 2023-06-14
MX2021015756A (es) 2022-01-27
US20220411439A1 (en) 2022-12-29
JP2022537385A (ja) 2022-08-25

Similar Documents

Publication Publication Date Title
MX2021008145A (es) Polimorfo de macrociclo de diarilo.
CO2020015226A2 (es) Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
DOP2022000082A (es) Heterociclos bicíclicos como inhibidores de fgfr
ECSP16088983A (es) 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET
MX2018000718A (es) Macrociclos de diarilo quirales y usos de los mismos.
ECSP099400A (es) Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa
NI201800141A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
IL276501A (en) CGAS inhibitors containing 2,3,4,5-tetrahydro-1H-pyrado[B-4,3]indoles for the treatment of autoinflammatory diseases
HN2003000416A (es) Derivados de pirrolopirimidina
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
ECSP11011257A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
CO6420343A2 (es) [1, 2, 4] triazolo [1, 5 -a] piridinas como inhibidores de cinasa
UY32712A (es) Compuestos bicíclicos y tricíclicos como inhibidores de kat ii
CL2019001669A1 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1.
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CO2017003538A2 (es) Inhibidores de histona desmetilasa derivados de 2-oxipirido[ 3,4-d]pirimidin-4-ol
NI200700318A (es) Benzocicloheptapiridinas como inhibidores de la tirosina quinasa de receptor met
CO2022000405A2 (es) Polimorfos de un inhibidor de cinasas macrocíclicas
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
PE20191789A1 (es) Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa
IL304595A (en) Bicyclic tetrahydrozepine derivatives for cancer treatment